Drug Information

Drug General Information
Drug ID
D0OW2S
Former ID
DNCL001707
Drug Name
AMG 145
Indication Hypercholesterolemia [ICD10:E78] Phase 3 [524291]
Company
Amgen Thousand
Target and Pathway
Target(s) Proprotein convertase subtilisin/kexin type 9 Target Info Modulator [532982]
WikiPathways PCSK9-mediated LDLR degradation
References
Ref 524291ClinicalTrials.gov (NCT01854918) Open Label Study of Long Term Evaluation Against LDL-C Trial-2. U.S. National Institutes of Health.
Ref 532982PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24;385(9965):331-40.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.